- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06852859
Dolor informado por el paciente y alivio de los síntomas durante tres meses después de la cirugía por hiperplasia prostática benigna
Dolor y alivio de síntomas informados por el paciente durante tres meses después de la cirugía por hiperplasia prostática benigna.
This is a prospective observational study in patients undergoing surgery for benign prostatic hyperplasia (BPH).
The purpose of the study is to investigate in great detail patients' recovery after surgery for BPH regarding pain, hematuria, urine leakage and use of pain-relieving medications for three months postoperatively. Patient-reported outcomes after three different surgical methods will be investigated: transurethral resection, transurethral vaporization and laser transurethral enucleation of the prostate (Green-LEP)
Research questions:
- How do patients rate their day-to-day pain during the first three months after surgery for BPH? How long does it take to be pain free?
- How does the patient estimate any day-to-day burning sensation during the first three months after surgery for BPH?
- How many painkilling tablets of a certain preparation and a certain strength take patients per day in the first three months after surgery for BPH?
- How long do patients have urinary leakage after surgery for BPH?
- Are the patients bothered by possible urine leakage and if so for how long after surgery for BPH?
- How long does one have macroscopic hematuria after surgery for BPH?
- How quickly are the patients' urinary tract problems affected according to the IPSS per month?
- Are the results on the above outcome measures different between the three TUR-P methods, TUV-P and Green LEP?
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Design and selection:
This is a prospective multicenter observational study in which patients undergoing TUR-P, TUV-P and GreenLEP for BPH are included. The subjects will be followed up with a self-assessment form that is completed daily for three months and then sent to the responsible researchers. After this, the research subjects will be followed up with sent out IPSS forms after six months, and then annually for up to five years. These are sent in stamped envelopes.
Participants:
The study will include 500 patients who undergo surgery for BPH at Alingsås hospital, Sjukhusen i Väster and Sahlgrenska University Hospital, as well as possibly an additional urology clinic in the future. The inclusion criteria include men over 50 years of age with diagnosed BPH and LUTS who have an indication for surgery with any of the three methods studied.
Outcome measures:
- Pain and burning will be assessed using the NRS (numeric scale) between 0 and 10 where 0 is defined as "no pain/burning" and 10 is defined as "worst imaginable pain/burning". The researchers fill in this day-by-day for three months
- Use of pain-relieving medications will be investigated with a table in which the research subjects enter drug names and sum up the number of tablets taken per day.
- Urine leakage will be examined by the research subjects checking either "Yes" or "no" on the question of whether they have had urine leakage on a daily basis.
- If this urine leakage has bothered the research subjects, it is investigated by ticking either "Yes" or "No" daily as a follow-up question to the previous one.
- The duration of hematuria will be examined by the research subjects checking either "Yes" or "No" on the question of whether they have had blood in the urine daily
- The change in LUTS measured by IPSS will be used to measure patient-perceived outcomes at baseline, after four, eight and twelve weeks, after six months and then annually for five years.
Data Analysis:
Descriptive statistics will be used to compile the PROMs data. Changes over time will be analyzed using repeated measures (ANOVA). Differences in outcome measures between the three different methods will be analyzed with the Mann-Whitney test for continuous, independent data pairs, and the Chi-Square test for categorical variables.
Ethical considerations:
The study will be conducted in accordance with the Declaration of Helsinki, and all participants will give their informed consent. Ethical approval will be sought from the Ethical Review Authority (EPM)
Significance and clinical relevance:
The results of this study will provide important insights into how patient-reported outcomes after benign prostate surgery can be used to improve surgical outcomes and patient counseling. The results will also be able to be used to compare outcome measures between the three different treatments used for BPH. By highlighting the patient's perspective, care can be developed to better meet the patients' needs and expectations, and by determining a "normal course" regarding these outcome measures, the results can also be used in the future to identify patients who deviate from the expected recovery course.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Joakim BE Strömberg, MD, PhD
- Número de teléfono: 46-768-341-327
- Correo electrónico: joakim.stromberg@vgregion.se
Ubicaciones de estudio
-
-
-
Alingsås, Suecia
- Reclutamiento
- Alingsås lasarett, department of general surgery, urology and orthopaedic surgery
-
Uddevalla, Suecia
- Aún no reclutando
- NU sjukvården, Uddevalla sjukhus, department of urology
-
-
Sweden
-
Kungälv, Sweden, Suecia
- Aún no reclutando
- Kungälvs sjukhus, department of urology
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients scheduled for surgery for benign prostatic hyperplasia
Descripción
Inclusion Criteria:
- Patients undergoing transurethral surgery for benign prostatic hyperplasia
- Singed informed consent to participate
Exclusion Criteria:
- Non-swedish speaking patients
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Patient treated by transurethral surgical procedure
Patients treated for BPH with surgery |
Thermocoagulation is used in contrast to the other methods Heat is used to vaporize prostate laser is used in contrast to the other methods |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in postoperative pain levels
Periodo de tiempo: Day-by-day for three months
|
Day-by-day registration of pain by NRS (numeric response scale) for pain. Anchorpoints: 0 (no pain) to 10 (worst possible pain) |
Day-by-day for three months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Use of analgesics postoperatively
Periodo de tiempo: Day-by-day for three months
|
Patients are to report all pain medication used day-by-day |
Day-by-day for three months
|
|
Duration of postoperative hematuria
Periodo de tiempo: Day-by-day for three months
|
The patients register the incidence of hematuria day-by-day by checking either "yes" or "no" |
Day-by-day for three months
|
|
Duration of postoperative leakage of urine
Periodo de tiempo: Day-by-day for three months
|
The patients record the incidence of leakage of urine day-by-day by checking either "yes" or "no" box |
Day-by-day for three months
|
|
Concerns about urine leakage
Periodo de tiempo: Day-by-day for three months
|
If the patients have checked the box "yes" for urine leakage, they are asked to record if they are bothered by this leakage or not by checking either "yes" or "no" box |
Day-by-day for three months
|
|
Changes in Lower Urinary Tract Symptoms as measured by the IPSS questionnaire
Periodo de tiempo: Month-by-month for 3 months
|
The patients are asked to complete the IPSS (International Prostatic Symptom Score) once a month. The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms. |
Month-by-month for 3 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Joakim BE Strömberg, MD, PhD, Sahlgrenska University Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades urogenitales masculinas
- Hiperplasia prostática
- Procedimientos quirúrgicos, operativo
- Procedimientos quirúrgicos urológicos
- Procedimientos quirúrgicos urogenitales
- Procedimientos quirúrgicos urológicos, hombre
- Prostatectomía
- Resección transuretral de la próstata
Otros números de identificación del estudio
- 2024-06211-01 EPM
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .